Advanced nanoparticle-enabled risperidone delivery for improved therapeutic outcomes of schizophrenia management: a review
RSP-loaded nanoparticles are a valuable innovation in SZ therapy through enhancing efficacy, minimizing side effects, and improving patient compliance. More clinical studies are warranted to determine their safety, long-term efficacy, and commercial viability for translation into the clinic.
Authors
- Mahalaxmi Rathnanand (ORCID: https://orcid.org/0000-0002-6339-2836)
- Vamshi Krishna Tippavajhala (ORCID: https://orcid.org/0000-0001-6540-9550)
- Akshay Shetty (ORCID: https://orcid.org/0000-0002-8494-8469)
- Pragathi Devanand Bangera
- Mahesha Keerikkadu (ORCID: https://orcid.org/0009-0007-3599-7364)
- Ashwin Kumar
Institutions
- Manipal Academy of Higher Education (IN)
Publication Details
- Journal
- Drug Development and Industrial Pharmacy
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1080/03639045.2025.2579655
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00